- Home
- NKSH vs CLLS Comparison
NKSH vs CLLS Comparison
Compare NKSH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- CLLS
- Stock Information
- Founded
- NKSH 1891
- CLLS 1999
- Country
- NKSH United States
- CLLS France
- Employees
- NKSH N/A
- CLLS N/A
- Industry
- NKSH Major Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- CLLS Health Care
- Exchange
- NKSH Nasdaq
- CLLS Nasdaq
- Market Cap
- NKSH 163.0M
- CLLS 143.4M
- IPO Year
- NKSH N/A
- CLLS 2007
- Fundamental
- Price
- NKSH $28.80
- CLLS $2.52
- Analyst Decision
- NKSH Strong Buy
- CLLS Buy
- Analyst Count
- NKSH 1
- CLLS 1
- Target Price
- NKSH $38.00
- CLLS $4.00
- AVG Volume (30 Days)
- NKSH 15.4K
- CLLS 227.4K
- Earning Date
- NKSH 08-13-2025
- CLLS 08-05-2025
- Dividend Yield
- NKSH 5.24%
- CLLS N/A
- EPS Growth
- NKSH N/A
- CLLS N/A
- EPS
- NKSH 1.77
- CLLS N/A
- Revenue
- NKSH $49,801,000.00
- CLLS $54,747,000.00
- Revenue This Year
- NKSH N/A
- CLLS $48.52
- Revenue Next Year
- NKSH $5.93
- CLLS $5.17
- P/E Ratio
- NKSH $16.24
- CLLS N/A
- Revenue Growth
- NKSH 2.21
- CLLS 351.26
- 52 Week Low
- NKSH $23.75
- CLLS $1.10
- 52 Week High
- NKSH $33.37
- CLLS $2.66
- Technical
- Relative Strength Index (RSI)
- NKSH 53.90
- CLLS 69.04
- Support Level
- NKSH $28.01
- CLLS $2.00
- Resistance Level
- NKSH $29.64
- CLLS $2.36
- Average True Range (ATR)
- NKSH 0.65
- CLLS 0.21
- MACD
- NKSH -0.09
- CLLS 0.05
- Stochastic Oscillator
- NKSH 40.51
- CLLS 87.21
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.